文献速递临床试验与 GCP

碳酸氢钠用于院内心脏骤停:一项随机临床试验

Sodium Bicarbonate for In-Hospital Cardiac Arrest: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

在丹麦21家医院开展的随机双盲安慰剂对照试验纳入913例院内心脏骤停成人患者,比较碳酸氢钠与安慰剂对持续自主循环恢复的影响。碳酸氢钠组与安慰剂组持续自主循环恢复率分别为39%与37%,差异无统计学意义;30天生存率与良好神经功能结局亦无显著差异。结果不支持院内心脏骤停常规使用碳酸氢钠。

要点

  • 碳酸氢钠未提高院内心脏骤停患者的持续自主循环恢复率。
  • 30天生存率与良好神经功能结局在两组间无显著差异。
  • 碳酸氢钠组心脏骤停后碱中毒和高钠血症更常见。

核心结论

  • 在院内心脏骤停成人中,碳酸氢钠与安慰剂在持续自主循环恢复方面无显著差异。
  • 结果不支持对院内心脏骤停患者常规给予碳酸氢钠。

研究设计与样本

  • 随机、平行分组、双盲、安慰剂对照临床试验,在丹麦21家医院开展。
  • 参与者为接受至少1剂肾上腺素的院内心脏骤停成人,2023年2月6日至2026年2月11日入组。
  • 共筛查2913例,随机化913例,其中779例纳入主要分析(碳酸氢钠组372例,安慰剂组407例)。
  • 干预为静脉给予碳酸氢钠(最多100 mmol)或安慰剂。
  • 主要结局为持续自主循环恢复;关键次要结局为30天生存及30天良好神经功能结局(改良Rankin量表评分0至3分)。

主要发现

  • 30天生存:碳酸氢钠组45例(12%)、安慰剂组37例(9.1%)(风险比1.25 [95%CI 0.84-1.88])。
  • 30天良好神经功能结局:碳酸氢钠组30例(8.1%)、安慰剂组22例(5.4%)(风险比1.39 [95%CI 0.82-2.34])。
  • 心脏骤停后碱中毒和高钠血症在碳酸氢钠组更常见。

临床怎么用

  • 院内心脏骤停时不推荐常规使用碳酸氢钠,应基于个体情况权衡利弊。
  • 使用碳酸氢钠时需警惕心脏骤停后碱中毒和高钠血症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with in-hospital cardiac arrest have poor outcomes. Sodium bicarbonate is commonly administered during cardiac arrest, but the effects on clinical outcomes are unknown. OBJECTIVE: To determine whether administration of sodium bicarbonate during in-hospital cardiac arrest increases the proportion of patients with return of spontaneous circulation. DESIGN, SETTING, AND PARTICIPANTS: Randomized, parallel-group, double-blind, placebo-controlled clinical trial conducted at 21 hospitals in Denmark. Participants were adults with in-hospital cardiac arrest, who received at least 1 dose of epinephrine. Patients were enrolled from February 6, 2023, to February 11, 2026, with the last 90-day follow-up conducted on May 4, 2026. Final statistical analysis was conducted on May 5, 2026. INTERVENTION: Sodium bicarbonate (up to 100 mmol) or placebo intravenously. MAIN OUTCOMES AND MEASURES: The primary outcome was sustained return of spontaneous circulation. Key secondary outcomes were survival at 30 days and survival at 30 days with a favorable neurologic outcome, defined by a score of 0 to 3 on the modified Rankin Scale (scores range from 0 to 6, with higher scores indicating greater disability). RESULTS: A total of 2913 patients with in-hospital cardiac arrest were screened; 913 patients were randomized, of which 779 were eligible for the primary analyses, with 372 randomized to receive sodium bicarbonate and 407 randomized to receive placebo. The median (IQR) age of patients was 73 (64-79) years and 502 were male (64%). Sustained return of spontaneous circulation occurred in 146 patients (39%) in the sodium bicarbonate group and 150 (37%) in the placebo group (risk ratio, 1.05 [95% CI, 0.88-1.24]; P = .62). At 30 days, 45 patients (12%) in the sodium bicarbonate group and 37 (9.1%) in the placebo group were alive (risk ratio, 1.25 [95% CI, 0.84-1.88]); a favorable neurologic outcome at 30 days occurred in 30 patients (8.1%) and 22 patients (5.4%), respectively (risk ratio, 1.39 [95% CI, 0.82-2.34]). Alkalosis and hypernatremia after cardiac arrest were more common in the sodium bicarbonate group. CONCLUSIONS AND RELEVANCE: There was no significant difference in sustained return of spontaneous circulation between sodium bicarbonate and placebo in adults with in-hospital cardiac arrest. These findings do not support routine administration of sodium bicarbonate for patients with in-hospital cardiac arrest. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05564130; ClinicalTrialsRegister.eu Identifier: 2022-501304-10-00.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Granfeldt A, Kirkegaard BL, Vallentin MF, et al. Sodium Bicarbonate for In-Hospital Cardiac Arrest: A Randomized Clinical Trial. JAMA. 2026. PMID: 42273960. doi:10.1001/jama.2026.10628

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。